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The hedgehog (Hh) family of intercellular signaling proteins is intricately linked to the development and patterning
of almost every major vertebrate organ system. In the skin, sonic hedgehog (Shh) is required for hair follicle
morphogenesis during embryogenesis and for regulating follicular growth and cycling in the adult. We recently
described the identiﬁcation and characterization of synthetic, non-peptidyl small molecule agonists of the Hh
pathway. In this study, we examined the ability of a topically applied Hh-agonist to modulate follicular cycling in
adult mouse skin. We report that the Hh-agonist can stimulate the transition from the resting (telogen) to the growth
(anagen) stage of the hair cycle in adult mouse skin. Hh-agonist-induced hair growth caused no detectable dif-
ferences in epidermal proliferation, differentiation, or in the endogenous Hh-signaling pathway as measured by
Gli1, Shh, Ptc1, and Gli2 gene expression when compared with a normal hair cycle. In addition, we demonstrate that
Hh-agonist is active in human scalp in vitro as measured by Gli1 gene expression. These results suggest that the
topical application of Hh-agonist could be effective in treating conditions of decreased proliferation and aberrant
follicular cycling in the scalp including androgenetic alopecia (pattern hair loss).
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Hedgehog (Hh) was originally identified in Drosophila as a
regulator of cell-fate determination during embryogenesis
(Nu¨sslein-Volhard and Wieschaus, 1980). The three verte-
brate Hh homologs, Sonic, Desert, and Indian (Shh, Dhh,
and Ihh), perform essential roles in many of the fundamental
processes that occur during the development and pattern-
ing of essentially every major organ (McMahon et al, 2003).
In addition to its role during embryogenesis, Shh has been
shown to be involved in the maintenance of stem cells in the
adult (Beachy et al, 2004). Signaling activity in the Hh path-
way begins with the binding of the Hh ligand to its receptor,
Patched (Ptc), a 12-transmembrane domain protein (for a
comprehensive review of the pathway, see Lum and Be-
achy, 2004). In the absence of the Hh ligand, Ptc suppress-
es the activity of the seven-transmembrane protein
Smoothened (Smo); however, when Hh is present and
binds to Ptc, the repression of Smo is suspended, resulting
in the activation of the Gli family of transcription factors
(Gli1, Gli2, Gli3). Upon pathway stimulation, these tran-
scription factors translocate to the nucleus and effect target
gene transcription. Members of the pathway, including Gli1
and Ptc1, are themselves transcriptional targets, and their
own induction serves as a mechanism of pathway self-reg-
ulation.
During skin development, Shh plays a vital role in the
morphogenesis of hair follicles. Mice lacking Shh activity
exhibit follicles arrested at the hair germ stage of develop-
ment (St-Jacques et al, 1998; Chiang et al, 1999). Although
hair placodes are normal in spacing and number, dermal
papillae fail to form correctly and proliferation in the follicular
epithelium is impaired. Subsequently in the adult, Shh
serves as a key regulator of follicular growth and cycling as
it is able to induce the transition from the resting (telogen) to
the growth stage (anagen) of the hair follicle cycle (Sato
et al, 1999; Stenn and Paus, 2001). Conversely, antibodies
that block the activity of Shh are able to prevent hair growth
in adult mice (Wang et al, 2000). Although no hair is pro-
duced, the hair follicles do undergo limited proliferation that
results in the formation of small, bulb-like structures that
express markers of follicular differentiation. Similar results
were observed when Shh / skin was grafted onto recip-
ient mice and analyzed (St-Jacques et al, 1998; Chiang
et al, 1999). Collectively, these experiments indicate that
Shh is not required to initiate anagen but is absolutely re-
quired for correct follicular morphogenesis and hair pro-
duction. The Hh pathway has also recently been implicated
in the regulation of sebaceous gland development and dif-
ferentiation in the skin (Allen et al, 2003; Niemann et al,
2003).
The analysis of the Hh-signaling pathway in adult mouse
skin has been complicated and hindered by the embryonic
lethality of the majority of mouse models involving altera-
tions in the pathway. Shh, Gli2, Ptc1, and Smo knockout
mice all fail to develop to term (Chiang et al, 1996; Goodrich
et al, 1997; Mo et al, 1997; Zhang et al, 2001). In addition,
the analysis of transgenic mouse models in which various
components of the Hh pathway have been expressed
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in different contexts (Oro et al, 1997; Xie et al, 1998;
Grachtchouk et al, 2000; Nilsson et al, 2000; Sheng et al,
2002; Grachtchouk et al, 2003; Mill et al, 2003; Hutchin et al,
2005), has primarily focused on the role of the Hh pathway
in follicular morphogenesis and basal cell carcinoma (BCC)
development and not on postnatal hair cycling.
We have previously described the identification and
characterization of synthetic, non-peptidyl small molecules
that bind to Smo and function as Hh pathway agonists
(Frank-Kamenetsky et al, 2002). These molecules feature
many properties that make them attractive as potential
therapeutic agents including their low-nanomolar potencies
and favorable pharmacokinetic profiles in targeted tissues.
Importantly, the Hh-pathway agonists (Hh-agonist) can ac-
tivate Hh-signaling in a wide variety of in vitro and in vivo
assays (Frank-Kamenetsky et al, 2002; Wichterle et al,
2002; Gabay et al, 2003; Machold et al, 2003; Harper et al,
2004, unpublished data).
In this study, we have investigated the ability of topically
applied Hh-agonist to modulate the Hh pathway in adult
mammalian skin in vivo. Here we report that a single topical
dose of Hh-agonist can stimulate the telogen to anagen
transition in adult mouse hair follicles. When compared with
a normal hair cycle, hair growth occurs without causing
detectable differences in epidermal proliferation, differenti-
ation, or in the expression of Hh-signaling pathway com-
ponents. Furthermore, topical Hh-agonist can induce Gli1
gene expression in human scalp in vitro. These results sug-
gest that the topical application of Hh-agonist can be used
to activate the pathway in vivo and may be a novel and
effective method to treat conditions of decreased prolifer-
ation and aberrant follicular cycling in skin such as andro-
genetic alopecia (pattern hair loss).
Results
In order to determine if Hh-agonist could cause hair growth,
7-wk-old C57BL/6NCrlBR (C57BL/6) mice were topically
treated with Hh-agonist. Hair growth in this strain has been
extensively studied and the timing of the stages of depilat-
ion-induced anagen have been rigorously characterized (for
a comprehensive review, see Mu¨ller-Ro¨ver et al, 2001).
From weeks 7 to 12 of postnatal life, C57BL/6 mice are in
the telogen, or resting stage, of the hair cycle, which pro-
vides a large window of time to assay for anagen induction
in the absence of endogenous hair growth.
Prior to assaying for hair growth, Hh-agonist was pre-
pared in a vehicle designed for effective delivery (95% ac-
etone/5% dimethylsulfoxide (DMSO)) and the penetration
and pharmacokinetic properties of Hh-agonist were inves-
tigated. Hh-agonist was topically applied to the shaved
dorsal surface of 7-wk-old C57BL/6 male mice and the
concentration in skin and plasma was determined at various
times after application. Hh-agonist penetrated the skin
quickly as quantitative absorption occurred 15 min after
application and reached a maximum concentration (Cmax) of
13.3 mM 4 h after application with a half-life in skin of 84 h
(T1/2). In addition, after either a single dose or multiple top-
ical doses (eight), no Hh-agonist was detectable in the
plasma at any time point analyzed (up to 8 d). Therefore, the
topical application of Hh-agonist resulted in the quick,
quantitative, and restricted delivery to the skin without sys-
temic exposure.
Based on the pharmacokinetic data and previous studies
(Frank-Kamenetsky et al, 2002), Hh-agonist at various con-
centrations (0.003–0.3 mg per mL) was tested for its ability to
induce hair growth. 25 mL of Hh-agonist was topically ap-
plied once a day for 8 d to the shaved dorsal surface of 7-
wk-old C57BL/6 mice. Beginning 7–8 d after application,
the area of Hh-agonist application began to darken indicat-
ing that follicular melanogenesis was occurring (Slominski
and Paus, 1993). Subsequently, hair began to emerge after
10–11 d in the Hh-agonist treated, but not in vehicle-treated
skin (data not shown).
To determine the minimal number of doses required to
initiate anagen, 7-wk-old C57BL/6 male mice were treated
once a day with either vehicle or Hh-agonist (0.06 mg per mL)
at a concentration that induced hair growth with similar ki-
netics to depilation (Mu¨ller-Ro¨ver et al, 2001) for 1–8 d on
two areas of their shaved dorsal surface. Interestingly, one
topical dose of Hh-agonist was sufficient to induce anagen
and hair growth, whereas vehicle-treated skin remained in
telogen (Fig 1A). In general, complete hair growth occurred
in areas treated with Hh-agonist (Fig 1A) and was restricted
to the area of topical application (Fig 1A). Light microscopy
analysis of skin sections from Hh-agonist-treated mice re-
vealed a clear demarcation between telogen and anagen
follicles at the boundary of Hh-agonist application (Fig 1C).
In contrast, hair follicles from vehicle-treated skin were all in
telogen (Fig 1B).
In order to more accurately characterize Hh-agonist-in-
duced hair growth, 7-wk-old shaved C57Bl/6 mice were
treated with one topical dose of Hh-agonist and skin sam-
ples obtained at various time points over the course of the
induced hair cycle were analyzed by light microscopy and
immunohistochemistry (Fig 2). Skin samples from depilated
mice were used as a reference since the timing of the stag-
es of a depilation-induced hair cycle are well characterized
and follow the same kinetics as a spontaneous, or naturally
occurring, hair cycle (Mu¨ller-Ro¨ver et al, 2001).
Proliferation and growth of the hair follicles, as detected
by bromodeoxyuridine (BrdU) immunohistochemistry, in re-
sponse to Hh-agonist treatment was first observed begin-
ning 2–3 d after topical application (data not shown). By day
4 there was a dramatic increase in the number of BrdU
positive cells in the growing hair follicles of Hh-agonist-
treated skin compared with either Hh-agonist-treated skin
at day 1 (compare Fig 2B and J to Fig 2A and I) or vehicle-
treated skin (data not shown) indicating that anagen had
been initiated. By 8 d after topical application, Hh-agonist-
treated skin exhibited correctly oriented hair follicles in
anagen VI. The hair follicles extended deep into the dermis
and BrdU positive cells were abundant in the follicular ma-
trix and outer root sheath cells (Fig 2C, D, K, L). The per-
centage of proliferative matrix cells in Hh-agonist-treated
skin based on BrdU labeling 8 d after treatment was
33.4%  1.3% compared with 36.9%  1.1% in depilated
skin. When the same analysis was performed 12 d after
treatment the percentage of proliferative matrix cells was
still quite similar regardless of the method of anagen
induction (35.7%  1.6% in Hh-agonist-treated skin
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compared with 33.1%  1.4% in depilated skin). In general,
there was no evidence of abnormal proliferation or histology
in the hair follicles, epidermis, or sebaceous glands of Hh-
agonist-treated skin (Fig 2A–D, I–L) when compared with
depilated skin (Fig 2E–H, M–P) at any equivalent time point
analyzed.
By day 18–19, both Hh-agonist and depilated skin had
entered into catagen (Fig 2Q, R) and by day 23 had com-
pleted the hair cycle and the follicles were once again in
telogen (Fig 2S, T). In addition, when compared by light
microscopy, hairs produced from Hh-agonist-treated and
depilated mice exhibited no obvious differences in length,
thickness, production and ratio of the four hair types (auc-
hene, awl, guard, and zig-zag), and pigmentation patterns
(data not shown). Thus, by all accounts, the hair cycle and
hair produced by Hh-agonist treatment are similar to those
of a normal hair cycle.
In order to characterize, at a molecular level, the mag-
nitude and temporal expression of the Hh-agonist-induced
Hh-signaling pathway response in skin, the relative mRNA
induction of Gli1, Shh, Ptc1, and Gli2 were determined dur-
ing the early events of anagen (days 0–10 after induction).
Mice were treated with either one topical application of Hh-
agonist, vehicle, or a depilatory agent to induce anagen and
RNA from skin at each time point was obtained and analy-
zed by quantitative RT-PCR.
Induction of Gli1, an early and consistent indicator of Hh
pathway activation (McMahon et al, 2003), and Shh was first
observed 3 d after Hh-agonist treatment and 4 d after de-
pilation (Fig 3A, B). By 2-way ANOVA analysis, a statistically
significant induction of both Gli1 and Shh, however, was
observed for both treatments beginning 5 d after anagen
initiation (Fig 3A, B, treatment, po0.01, time, po0.01). Rel-
ative mRNA levels remained elevated and appeared to level
off at day 9–10 corresponding to the anagen VI stage of the
hair cycle. The relative magnitude of Shh mRNA induction
(  100-fold) was strikingly higher compared with that of the
other genes analyzed (  20–25-fold for Gli1 and Ptc1 (Fig
3C), and  6–7-fold for Gli2 (Fig 3 D)). The overall temporal
pattern and relative level of Gli1 and Shh induction over the
time course was similar between the two methods of ana-
gen initiation with the exception that induction of the two
genes after Hh-agonist treatment occurred 1 d earlier.
Ptc1, the Hh protein receptor that is transcriptionally
regulated in response to Hh pathway activation (McMahon
et al, 2003), and Gli2, the functional mediator of Hh signal
transduction in the hair follicle (Mill et al, 2003), were both
induced at day 5 by Hh-agonist and depilation (Fig 3C, D). A
statistically significant induction was observed beginning at
day 6 for Ptc1 and day 7 for Gli2 (treatment, po0.01, time
po0.01). In contrast to Gli1 and Shh, the relative mRNA
levels of Ptc1 and Gli2 appeared to still be increasing at day
10. The levels of all four mRNAs remained elevated until the
onset of catagen at day 17–19, at which point they began to
decrease. By 21 d after anagen initiation, the levels of all
four mRNAs had returned to pre-treatment (telogen) levels
(data not shown). Most importantly, the temporal pattern
and magnitude of expression of Gli1, Shh, Ptc1, and Gli2 in
response to Hh-agonist treatment was similar to that ob-
served with depilation-induced anagen.
Since it is well established that aberrant Hh pathway ac-
tivity in skin can lead to abnormal differentiation and various
follicular hyperplasias including BCC (Hahn et al, 1996;
Johnson et al, 1996; Dahmane et al, 1997; Oro et al, 1997;
Xie et al, 1998; Aszterbaum et al, 1999; Grachtchouk et al,
2000; Nilsson et al, 2000; Sheng et al, 2002), the effect of
Hh-agonist on differentiation in the skin was analyzed.
Seven-wk-old C57BL/6 male mice were either treated with
one topical dose of vehicle, Hh-agonist, or depilated to in-
duce anagen. Although hair follicles from vehicle-treated
skin were still in telogen 10 d after treatment (Fig 4A) both
depilated (Fig 4F) and Hh-agonist-treated hair follicles
(Fig 4K) were in anagen VI of the hair cycle. At this sub-
stage of anagen, hair follicle size, proliferation, and hair
production are at their maximum.
To determine if Hh-agonist treatment resulted in epider-
mal hyperproliferation, Keratin 6 (K6) expression was ex-
amined. K6 is normally expressed in the companion layer of
the hair follicle (K6hf) but not in the inter-follicular epidermis
(Winter et al, 1998). Under certain conditions including
wounding and diseases that alter proliferation and differen-
tiation, however, expression of K6 is induced in the supra-
basal layers of the interfollicular epidermis (McGowan and
Figure 1
Anagen induction and hair growth in C57BL/6NcrlBR (C57BL/6)
mice treated with a single topical dose of hedgehog (Hh)-agonist.
(A) Seven-wk-old male mice were shaved and given a single 25 mL
topical application of vehicle (95% acetone/5% DMSO) or Hh-agonist
(0.06 mg per mL in vehicle, 120 mM) on their upper and lower dorsal
regions. Hair growth in the mice pictured is 13 d after topical appli-
cation. (B, C) Five-mm parasagittal paraffin sections were stained with
hematoxylin and eosin and analyzed by light microscopy. Vehicle (B) or
Hh-agonist (C) was applied to the right of the arrow. Skin was proc-
essed for analysis 14 d after treatment. Hair growth was restricted
to the area of topical application. hf, hair follicle. Scale bar (B, C)¼
200 mm.
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Coulombe, 1998). In all three groups analyzed (Fig 4B, G,
and L), K6 expression was restricted to the hair follicle and
there was no evidence of suprabasal expression indicating
that Hh-agonist treatment did not cause epidermal hyper-
proliferation.
Markers of early and late terminal differentiation in the
epidermis were also examined. Keratin 10 (K10) is ex-
pressed in the spinous layer of the epidermis as the process
of terminal differentiation begins (Fuchs and Green, 1980)
whereas loricrin, the major component of the cornified en-
velope, is expressed later in the granular layer (Mehrel et al,
1990). K10 expression was restricted to the suprabasal lay-
ers of the epidermis in both the depilated (Fig 4H), Hh-ago-
nist-treated (Fig 4M) and vehicle-treated skin (Fig 4C). In
addition, loricrin expression, in all three cases (Fig 4D, I, and
N), was detected in the granular layer and stratum corneum.
The correct expression of all three epidermal markers was
observed not only at anagen VI but at all other stages of the
induced hair cycle analyzed (data not shown). Finally, Ker-
atin 14 (K14), a marker of the proliferative basal layer of the
interfollicular epidermis and the outer root sheath of the hair
follicle (Coulombe et al, 1989), exhibited proper expression
in all skin samples analyzed (Fig 4 E, J, and O). The correct
expression of epidermal differentiation markers coupled
with the normal histology and proliferation observed (Fig 2)
suggests that Hh-agonist treatment did not affect the nor-
mal epidermal proliferation and differentiation of the skin
during anagen induction.
The long-term effects of Hh-agonist treatment on prolif-
eration and differentiation in mouse skin were also exam-
ined. Seven-wk-old mice were treated with either one
topical dose of vehicle or Hh-agonist to induce anagen.
Approximately 1 y later, skin from both groups was analyzed
by light microscopy and immunohistochemistry. Hair folli-
cles from both vehicle (Fig 5A)- and Hh-agonist (Fig 5B)-
treated skin were in telogen. Proliferation in both vehicle-
(Fig 5C) and Hh-agonist-treated (Fig 5D) skin, as analyzed
by BrdU immunohistochemistry, was minimal. A few BrdU
Figure 2
Light microscopy analysis of the
hedgehog (Hh)-agonist-induced hair
cycle. Five-mm parasagittal paraffin sec-
tions were stained with hematoxylin and
eosin (A–H, Q–T) or immunostained with
an antibody to BrdU (I–P) and analyzed by
light microscopy. Seven-wk-old C57BL/
6NcrlBR (C57BL/6) male mice were given
a single 25 mL topical dose of Hh-agonist
(0.06 mg per mL in vehicle) and skin was
isolated at the indicated day over the
course of the induced hair cycle. Depi-
lated skin was used as a control for ana-
gen induction. Hh-agonist (Ag)-treated
skin: A–D, I–L, Q, S; depilated skin (dep):
E–H, M–P, R, T. hf, hair follicle; m, matrix.
Scale bar¼ 100 mm.
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positive cells were detected in both the telogen-staged hair
follicles and the interfollicular epidermis (arrowheads in Fig
5C and D). In addition, the expression of the hyperprolifer-
ation-associated K6 was restricted to the hair follicle and
was not detected in the suprabasal layers of the epidermis
in either case (Fig 5E and F).
The expression of epidermal differentiation markers in
both vehicle- and Hh-agonist-treated skin was also similar.
K10 was restricted to the suprabasal layers of the epidermis
(Fig 5G and H), whereas loricrin was detected in the gran-
ular layer and stratum corneum (Fig 5I and J). Furthermore,
K14 expression was detected in the basal layer of the ep-
idermis and outer root sheath of the hair follicles in both
vehicle (Fig 5K) and Hh-agonist-treated skin (Fig 5L). Thus,
Hh-agonist treatment did not appear to result in any long-term
effects on the ability of the epidermis and hair follicles to
differentiate and proliferate normally.
In order to determine if Hh-agonist is active in human
skin, 6 mm skin punches from fetal scalp (18–22 wk) were
treated with Hh-agonist in vitro. At this stage of embryonic
development the hair follicles are already producing hair
(lanugo type). The agonist was topically applied to the ex-
posed surface of the skin once daily and activity was de-
termined by examining transcriptional targets of the Hh-
pathway using quantitative RT-PCR. After 4 d in culture,
treatment with vehicle did not induce Gli1, Ptch1, Gli2, or
Shh expression relative to untreated skin (Fig 6). Treat-
ment with Hh-agonist, however, resulted in the statistically
significant induction of Gli1, Gli2, and Ptc1 (Fig 6 (Gli1, Ptc1
3.5–4-fold; Gli2 2-fold)).
Discussion
We have reproduced a defined biological role of Shh in the
adult mouse, namely the ability to modulate hair growth and
follicular cycling, by the topical application of a small mol-
ecule agonist of the Hh-signaling pathway. This work further
validates the concept that Hh-signaling in the adult verte-
brate can be modulated in order to achieve a desired bi-
ological effect. One application of the Hh-agonist was able
to induce anagen in adult C57BL/6 mice. The resultant hair
cycle was indistinguishable from a normal hair cycle (de-
pilation model) with no detectable differences in the cycle
length, histology, expression of Hh-pathway genes, epider-
mal proliferation, differentiation, melanogenesis, or, ulti-
mately, in the hair produced. In addition, Hh-agonist
treatment did not appear to have any long-term effects on
the skin. Furthermore, we have also demonstrated that the
Hh-agonist is active in human scalp as measured by the
induction of Hh-pathway gene expression.
In addition to its necessity during hair follicle morpho-
genesis (St-Jacques et al, 1998; Chiang et al, 1999), the Hh-
signaling pathway is re-utilized during the postnatal cycling
of hair follicles (Sato et al, 1999; Wang et al, 2000). During
anagen, the Hh pathway components Gli1, Ptc1, Gli2, and
Shh have been localized by in situ hybridization to the ma-
trix, dermal papillae, and outer root sheath cells of the hair
follicle (Gat et al, 1998; Sato et al, 1999; Botchkarev et al,
2001; Oro and Higgins, 2003; Ikram et al, 2004; Lo Celso
et al, 2004). Subsequently, expression of the Hh-pathway
genes is downregulated when the hair follicles are in telogen
(Botchkarev et al, 2001; Oro and Higgins, 2003; this study).
We have determined the temporal Hh-pathway activation
that occurs during the course of a post-natal hair cycle us-
Figure 3
Time course of Sonic hedgehog (Shh) pathway gene expression in
skin following anagen induction in hedgehog (Hh)-agonist-treated
mice. The seven-wk-old C57BL/6NcrlBR (C57BL/6) male mice were
treated once with either 25 mL of vehicle, Hh-agonist (0.06 mg per mL in
vehicle), or a depilatory agent on their dorsal surface. Skin from each
group (n¼ 4) was harvested at days 0–10 after treatment and RNA was
isolated. Quantitative RT-PCR was used to analyze the expression of
Gli1 (A), Shh (B), Ptc1 (patched-1) (C), and Gli2 (D). Values are graphed
as a relative fold induction compared with the vehicle-treated sample at
time zero using glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
as a reference gene. GAPDH levels did not vary significantly as a
function of treatment or time. Statistical significance was determined
by performing a two-way ANOVA analysis with Bonferroni post-tests
(po0.05). Asterisk () indicates the time point at which statistically sig-
nificant induction begins. There was no significant induction of any of
the Hh pathway genes in the vehicle-treated samples. Error bars rep-
resent  SEM.
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ing two distinct methods to initiate hair growth. Hh-pathway
gene expression was first detected 3–4 d after anagen in-
itiation (Fig 3; see also Sato et al, 1999). The timing of Hh-
pathway signaling activation coincides with the transition
from the anagen II to anagen III stage of the hair cycle. At
this stage, the follicular matrix cells begin to surround the
dermal papillae cells and form the hair bulb. Proliferation in
the bulb increases, formation of the inner root sheath and
hair shaft begins, and the hair follicles extend deep into the
subcutis (Mu¨ller-Ro¨ver et al, 2001). Previous work has
shown that in the absence of Shh activity, both the epithelial
and mesenchymal (dermal papillae) portions of the bulb
structure do not form properly despite the expression of
markers of mature follicular differentiation (St-Jacques et al,
1998; Chiang et al, 1999; Wang et al, 2000). Taken together,
these data suggest that Shh is required for the proper for-
mation of the hair follicle bulb and hair production during the
postnatal hair cycle. Expression of Gli1, Shh, Ptc1, and Gli2
continued over the course of anagen and their levels de-
creased as the hair follicles entered catagen and had re-
turned to baseline when the follicles were once again in
telogen (Fig 3; data not shown). Hh-signaling may therefore
also be required for the sustained proliferation of matrix
cells that occurs over the course of anagen and hair
production.
Interestingly, the temporal pattern and magnitude of Gli1,
Shh, Ptc1, and Gli2 gene expression were similar whether
anagen was initiated with Hh-agonist or by depilation. This
suggests that the Hh-pathway transcriptional activation that
occurs 3–4 d after Hh-agonist treatment is due to the en-
dogenous response of the proliferating hair follicles as they
enter anagen (this study; Sato et al, 1999) and not primarily
as a direct result of Hh-agonist stimulation. How then does
Hh-agonist initiate anagen? In telogen skin there must be a
small population of a particular cell type(s) that is responsive
to Hh-agonist early after topical application. In a fashion
consistent with the paradigm of Hh-signaling (McMahon
et al, 2003), direct stimulation of this cell type may then
influence the same or adjacent cell type(s) to mediate the
early events of anagen through a different signaling path-
way. Further experiments will be necessary to determine the
exact cell type(s) in the skin that are being stimulated by the
Hh-agonist and how that stimulation mediates the early
events of anagen induction.
The non-peptidyl, small molecule Hh-agonists contain
multiple characteristics that make them attractive as po-
tential therapeutic agents (Frank-Kamenetsky et al, 2002).
When applied topically, the Hh-agonist is absorbed quickly
and quantitatively. Importantly, topical application of the
Hh-agonist results in restricted delivery and activity to the
applied area while avoiding systemic exposure (Fig 1A, C).
By regulating the amount of Hh-agonist delivered the bio-
logical effect can be regulated. In the case of anagen in-
duction, a small amount is enough to trigger hair growth that
occurs without causing any detectable differences when
compared with a normal hair cycle. Collectively, these
properties of the Hh-agonist class of compounds make
them suitable candidates for potential therapeutic indica-
tions that require topical application.
Androgenetic alopecia (also called male pattern hair loss)
is the most common type of genetic-based hair loss. Pat-
tern hair loss is characterized by both a progressive short-
ening of anagen and an increased time period between
exogen (hair shedding) and anagen induction that leads to a
decrease in hair density. As affected hair follicles continue
to cycle, they undergo a process of progressive miniatur-
ization. Concurrently, the size of the dermal papillae, which
is known to correlate with the size of the hair follicle and hair
shaft produced, also decreases (Hardy, 1992; Paus and
Cotsarelis, 1999; Messenger, 2003). The end result is the
Figure 4
Epidermal differentiation in hedgehog
(Hh)-agonist-treated mouse skin. Five-
mm parasagittal paraffin sections from
vehicle, depilated, or Hh-agonist-treated
mouse skin were stained with hem-
atoxylin and eosin (A, F, K) or immuno-
stained with antibodies to K6 (B, G, L),
K10 (C, H, M), loricrin (D, I, N), and K14
(E, J, O) and subsequently analyzed by
light microscopy. Seven-wk-old C57BL/
6NcrlBR (C57BL/6) 6 male mice were
given a single 25 mL topical application
of either vehicle or Hh-agonist (0.06 mg
per mL in vehicle). Depilated skin was
used as a control for anagen induction.
Skin was processed for analysis 10 d
after treatment during the anagen VI
stage of the hair cycle. Vehicle (veh)-
treated skin: A–E; depilated skin (dep):
F–J; Hh-agonist (Ag)-treated skin: K–O.
Scale bar (A–O)¼ 100 mm. Scale bar in
inset (C, D, H, I, M, and N)¼10 mm.
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production of smaller, unpigmented vellus hairs instead of
larger, pigmented terminal hairs. Although the follicles do
progressively get smaller, the overall scalp follicle density
appears to be preserved until late in the course of hair loss
when follicles are eventually destroyed (for a thorough de-
scription, see Olsen, 2003).
Since scalp affected with pattern hair loss has a higher
percentage of hair follicles in telogen, the ability of Hh-ago-
nist to promote anagen suggests that it may be useful as a
potential therapeutic agent. The Hh-agonist may also en-
hance follicular proliferation and the size, proliferation, and/
or organization of the dermal papillae in hair follicles affect-
ed by pattern hair loss. Ultimately, this potential combina-
tion of increasing the percentage of follicles in anagen and
helping to restore a more normal follicular architecture may
have a positive effect on hair growth. We have shown that
the Hh-agonist is able to activate the Hh pathway in human
scalp (Fig 6). Preliminary experiments suggest that adult
scalp, and in particular, alopecic scalp, is also responsive to
Hh-agonist as measured by Gli1 induction (data not shown).
Although these data are compelling, the physiological re-
sponse to Hh-pathway activation in normal and human
scalp affected with pattern hair loss needs to be determined
in an in vivo context. In conclusion, we propose that the use
of small molecule agonists of the Hh pathway may be a
potential therapeutic agent in the treatment of male and
female pattern hair loss.
Materials and Methods
Animal studies All animals were treated in accordance with
protocols approved by the Institutional Animal Care and Use Com-
mittee at Curis, Inc. (Cambridge, Massachusetts). C57BL/6 mice
were obtained from Charles River Laboratories (Wilmington, Mas-
sachusetts). Hh-Ag 1.8, a soluble derivative from the recently
characterized, Biaryl class of Hh agonists (Frank-Kamenetsky et al,
Figure 5
Long-term effects of hedgehog (Hh)-agonist treatment on epider-
mal differentiation in mouse skin. Five-mm parasagittal paraffin sec-
tions from vehicle-(A, C, E, G, I, K) or Hh-agonist-treated (B, D, F, H, J,
L) mouse skin were stained with hematoxylin and eosin (A, B) or
immunostained with antibodies to BrdU (C, D), K6 (E, F), K10 (G, H),
loricrin (I, J), and K14 (K, L) and subsequently analyzed by light mi-
croscopy. Seven-wk-old C57BL/6NcrlBR (C57BL/6) male mice were
given a single 25 mL topical application of either vehicle or Hh-agonist
(0.06 mg per mL in vehicle). Skin from vehicle- and Hh-agonist-treated
mice was obtained and processed for analysis  1 y after treatment.
Scale bar (A, B)¼100 mm. Scale bar (C–L)¼50 mm. Scale bar in inset
(G–J)¼ 10 mm. Arrowheads indicate BrdU positive cells (C and D).
Figure6
Hedgehog (Hh) pathway gene induction in hedgehog (Hh-)agonist-
treated fetal scalp. Human fetal scalp skin was cultured and topically
treated once daily with either 8 mL of vehicle or Hh-agonist (0.15 mg per
mL in vehicle). RNA was isolated after 4 d in culture. The relative mRNA
fold induction of Gli1, Ptc1 (patched-1), and Gli2 due to Hh-agonist
treatment was statistically significant compared with vehicle (po0.01,
n¼ 4) as analyzed by the student’s t-test. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as a reference gene and did not
vary significantly due to treatment. The relative mRNA fold induction
was determined by using no treatment as a reference. The results are
the average of four different experiments. Each experiment was per-
formed in duplicate. Error bars represent  SEM.
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2002) was used in all of these experiments. Details of the Hh-
agonist class of small molecules are presented in the issued US
Patent No. US 6,683,192 which can be examined at the following
website: http://www.uspto.gov/patft/. Hh-Ag 1.8 is available for
research use from Curis under a material transfer agreement. For
all experiments, Hh-Ag 1.8 (subsequently referred to as Hh-ago-
nist) was diluted in a vehicle of 95% acetone/5% DMSO (Sigma, St
Louis, Missouri) from an original 10 mg per mL DMSO stock. A
volume of 25 mL of Hh-agonist or vehicle was applied with a
pipetman to the shaved dorsal surface of 7-wk-old male mice. As a
control for anagen induction, 7-wk-old C57BL/6 male mice were
depilated with Nair (Carter-Wallace, New York, New York). The
mice were shaved on the dorsal surface and the depilating agent
was applied for 2 min, removed, and the depilated area was rinsed
with H2O. During all procedures the mice were temporarily anest-
hetized using a mixture of isoflurane (Baxter, Deerfield, Illinois) and
oxygen.
Hh-agonist concentration determination in skin and plasma
Seven-wk-old C57BL/6 male mice were treated with a single 25 mL
topical dose of Hh-agonist (0.06 mg per mL in vehicle, 120 mM) or
vehicle. Skin and blood samples were collected at various time
points after topical administration. Treated skin was cleaned three
times with alcohol pads (Kendall, Mansfield, Massachusetts) prior to
isolation in order to remove any Hh-agonist that may not have pen-
etrated the skin. Approximately 20–30 mg of treated skin was ho-
mogenized in 1 mL of phosphate buffered saline (PBS). Three
1.5 mL ethyl acetate extractions of the homogenate were obtained
and condensed by evaporation. The compound extracts were then
reconstituted in 100 mL of acetonitrile. To isolate the Hh-agonist
from blood, 100 mL of plasma was mixed with 200 mL of aceto-
nitrile, vortexed, and centrifuged for 10 min 8,160 g. The supe-
rnatant was isolated and subjected to LC-MS/MS. 10 mL of an
internal standard was added to each sample. Chromatographic
separation was achieved using a 5 mm, 2.1  30 mm XTerre MS
C18 column (Waters, Milford, Massachusetts) with a gradient mo-
bile phase of (A) acetonitrile:water:formic acid (5:95:0.1, vol/vol/vol)
and (B) acetonitrile:water:formic acid (95:5:0.1, vol/vol/vol). The
analytes were detected with a PE Sciex API 3000 triple quadrupole
mass spectrometer (Applied Biosystems, Foster City, California).
Precursor and product ions of the Hh-agonist (m/z 570.1, m/z
212.0) and the internal standard (m/z 436.2, m/z 150.9) were mon-
itored in the multiple reaction monitoring (MRM) model. Standards
were prepared by adding known amounts of the Hh-agonist to
known amounts of untreated skin and plasma samples. The Hh-
agonist was detectable to levels of 1 ng per mL. Measurements of
each time point and tissue were performed in triplicate.
Quantitative PCR analysis RNA from mouse and human skin was
isolated using the RNeasy mini kit (Qiagen, Valencia, California)
and cDNA was synthesized using established protocols. The cDNA
was assayed by quantitative PCR using primers and probes spe-
cific for mouse and human Gli1, Gli2, Ptc1, Shh, and GAPDH
(Qiagen and Applied Biosystems). All quantitative PCR assays
were performed using an ABI prism 7700 sequence detector and
the data were analyzed using ABI prism sequence detections sys-
tems version 1.7 (Taqman; Applied Biosystems). Statistical analysis
of the data was performed using the GraphPad Prism program
(version 4.0a, GraphPad Software, San Diego, California).
Histological analysis and immunohistochemistry Mouse skin
was fixed overnight at 41C with either 4% paraformaldehyde (Elec-
tron Microscopy Sciences, Hatfield, Pennsylvania) in PBS or
Bouin’s fixative (Sigma) and subsequently processed for paraffin
embedding and sectioned. For BrdU analysis, mice were given an
intraperitoneal injection of BrdU (Zymed, South San Francisco,
California) 2–3 h prior to obtaining tissue. For general histological
analysis, 5 mm parasagittal paraffin sections were stained with
hematoxylin and eosin (H&E). Immunohistochemistry was per-
formed according to standard procedures with antibodies against
K6, K10, K14, and loricrin (Covance, Berkeley, California). BrdU
immunohistochemistry was performed using a detection kit from
Zymed. The percentage of proliferating epidermal cells in the hair
follicle matrix was determined by dividing the number of BrdU
positive matrix cells by the total number of matrix cells in a given
follicle and multiplying by 100. Four random anagen VI staged-hair
follicles from three separate mice in each treatment group (day 8
and 12, depilation and Hh-agonist) were chosen and the BrdU
positive and total matrix cells were counted.
Human scalp skin explants Fetal human scalp (18–22 wk of
gestation) was procured by Advanced Bioscience Resources
(Alameda, California). Six-mm skin punches were made using der-
mal biopsy punches (Miltex, Bethpage, New York) and cultured in
Biocoat Collagen I coated 3.0 micron Transwell tissue culture
plates (Becton Dickinson Labware, Bedford, Massachusetts). Skin
punches were cultured in RPMI 1640 media (changed daily)
supplemented with 10% fetal bovine serum, glutamax, penicillin,
streptomycin, and gentamicin (Gibco-BRL, Gaithersburg, Mary-
land) for 4 d. Hh-agonist (0.15 mg per mL in vehicle) was applied
topically to the air-exposed, epidermal surface of the skin punches
once a day. Prior to RNA isolation, the skin punches were quick
frozen in liquid nitrogen.
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